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Background: Anti-epidermal-growth-factor-receptor (EGFR) therapies in combination
with radiotherapy are being studied on de-escalation clinical trials for HPV-related
oropharyngeal cancer (OPC) patients. The HPV16-E5 oncoprotein increases recycling
of activated EGFR to the cell surface, enhancing factor signal transduction. Our
aim was to evaluate viral HPV16-E5 oncogene expression as well as EGFR and
phosphorylated-EGFR (pEGFR), protein levels as biomarkers for clinical outcome in a
retrospective cohort of OPC patients.
Methods: Formalin-fixed-paraffin-embedded OPCs were collected from 1990 to
2013. OPC samples containing HPV-DNA were subject to viral E6∗I mRNA detection
and p16INK4a immunohistochemistry (IHC). HPV16-positive cases were evaluated for
HPV16-E5 (RT-PCR) and EGFR/pEGFR (IHC). A stratified and matched random sample
of HPV-negative samples was used as control and evaluated for EGFR/pEGFR. Overall
survival (OS) and disease free survival (DFS) estimates were assessed for locally
advanced OPC patients (stage III, IVa,b 7th edition).
Results: Among 788 OPC patient samples, 53 were double positive for
HPV16-DNA/p16INK4a. HPV16-E5 expression was found in 41 of 53 samples (77.4%).
EGFR expression was observed in 37.7 vs 70.8% of HPV16-positive vs HPV-negative
samples, respectively; (adjusted OR = 0.15) 5% CI = 0.04–0.56]). Expression
of pEGFR followed an inverse pattern with 39.6 and 24.9% detection in HPV16-
positive and HPV-negative samples; (adjusted OR = 1.58 [95% CI = 0.48–5.17]).
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Within HPV16-positive cases, no association between HPV16-E5/EGFR nor pEGFR was
observed. With a median follow-up of 39.36 months (min = 0.03 – max = 272.07), the
combination of HPV status and EGFR or pEGFR expression were predictors of better
OS (p < 0.001, for both) and DFS (p < 0.001 for EGFR and p = 0.003 for pEGFR).
Conclusions: HPV16-E5 is highly expressed on HPV16-positive OPCs. Interestingly,
HPV16-positive cases expressed significantly more pEGFR while HPV-negative cases
expressed more EGFR. The combinations of HPV status and EGFR or pEGFR may be
useful biomarkers for evaluating prognosis outcome in OPC patients.
Keywords: head and neck cancer, oropharyngeal cancer, Human Papillomavirus, HPV, EGFR, pEGFR, HPV16,
HPV16-E5
INTRODUCTION
Chronic infection by oncogenic Human Papillomaviruses
(HPVs) is the principal cause of the increasing incidence rates
of oropharyngeal carcinoma (OPC) (1).
Viral transformation concurs with a lower mutational burden,
resulting in better prognosis for patients with HPV-related
OPCs (2). Given the high morbidity associated with current
treatments (3), the scientific community is seeking de-escalation
protocols aiming at maintaining the cure rates while reducing
toxicity. Therapies targeting the Epidermal Growth Factor
Receptor (EGFR) have been proposed as de-escalation strategies
in HPV-related OPC patients, as an alternative to cisplatin
when given concurrently with radiation therapy, attempting to
reduce cisplatin side-effects (4, 5). Other de-escalation therapies
include reduction of radiation dose given in combination
with chemotherapy as primary treatment, reduced dose of
radiotherapy with or without cisplatin or reduction of adjuvant
chemo-radiotherapy dose following primary treatment with
surgery (4, 5). EFGR is overexpressed in 90% of head and neck
squamous cell carcinomas (HNSCC) (6). Nevertheless, there
is limited evidence supporting the role of anti-EGFR therapy
in HPV-related cancers, as alteration in EGFR levels in OPCs
does not correlate with HPV status (7, 8), and clinical data
remain controversial (7). Ligand-dependent EGFR activation
leads to auto-phosphorylation, and the activated form pEGFR is
the responsible molecular species that triggers the downstream
signaling cascade, eventually stimulating cell division (9).
Association with HPV infection, EGFR expression level, and
history of tobacco exposure are well-characterized prognosis
factors in HNSCC: HPV-related transformation is associated
with improved outcome (2); EGFR overexpression is associated
with poor prognosis (10); and tobacco may contribute to
increased EGFR expression through increased local hypoxia in
tumor tissue (6). Along this line, pEGFR has recently been
described as a prognosis biomarker related to poorer outcomes
in HNSCC (9, 11).
The direct effects of the E6 and E7 HPVs oncoproteins
at inactivating respectively p53 and retinoblastoma tumor
suppressor proteins and thereby disturbing cell cycle regulation
are well known as the hallmarks of HPVs-related transformation
(5, 12). However, the functions of the third viral oncoprotein,
E5, remain poorly understood (13). Expression of HPV16-E5
results in diverse effects, modifying the membrane chemistry
and influencing a variety of pathways involved in growth factor-
dependent cell proliferation, immune recognition, and altered
response to extrinsic and intrinsic pro-apoptotic signals (14). In
the present work we have focused on the ability of HPV16-E5 at
inhibiting endosomal acidification, thereby promoting recycling
of activated pEGFR to the cell surface (15, 16). Previous studies
have shown that HPV16-E5 encoding transcripts are variably
expressed in HPV-related HNSCC, and that E5 gene expression
correlates with EGFR overexpression in HPV-related OPC (13).
Current data on the differential response of OPCs to anti-EGFR
therapies as a function of the HPV status are still inconsistent
and importantly, 20% of HPV-related OPSCC patients fail to
treatment (2). Here we have analyzed for the first time HPV16-E5
expression, EGFR and pEGFR cellular levels, as well as smoking
status in a retrospective cohort of OPC patients. In an era where
anti-EGFR therapies are being studied on de-escalation clinical
trials we aimed at evaluating the prognostic and predictive values




We carried out a large retrospective cohort study (17), to
assess the prognostic and predictive value of HPV-related
carcinogenic biomarkers, on consecutively selected OPC cases
from four different hospitals from Catalonia (Catalan Institute
of Oncology-ICO-Hospital Universitari de Bellvitge; Hospital
de Sant Pau, Hospital del Mar and Hospital Parc Taulí) from
1990 to 2013. The current study is nested within this larger
cohort and was designed to evaluate the variation in EGFR
and pEGFR cellular levels, as well as in HPV16-E5 expression,
in the context of clinical outcomes. All HPV16-positive cases
[as defined by double positivity for HPV-DNA and p16INK4a,
(n= 53, 6.7%) were eligible to participate. A random set of HPV-
negative samples (n= 174) matched for tobacco use were chosen
as control group [random sample 1:3 for smokers (<20 cigarettes
a day or≥20 cigarettes a day) and 1:1 for non-smokers]. The 1–3
matching for non-smokers was not possible due to limited sample
size in this group.
Cases were confirmed by anatomopathology and metastatic
patients were discarded (7th TNM edition). Demographic and
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clinical information was extracted from the corresponding
clinical reports. Overall survival (OS) and disease free survival
(DFS) were assessed up to five years after diagnosis. All methods
were carried out in accordance with relevant guidelines and
regulations. The protocol was approved by the Institutional
Review Broad and ethical committee of each participating
hospital (PR323/14).
Laboratory Analysis
Biomarker assessment was centralized at the Catalan Institute
of Oncology (Barcelona, Spain) in collaboration with Hospital
General de L’Hospitalet (Barcelona, Spain) and the German
Cancer Research Center (DKFZ, Heidelberg, Germany), using
OPC formalin-fixed paraffin-embedded (FFPE) samples. The
detailed methods for immunohistochemistry (IHC), HPV-DNA
detection, genotyping, and HPV16-E6∗I mRNA assessment have
been reported elsewhere (18). Briefly, hematoxylin and eosin
stained slides were used to confirm presence and estimate the
proportion of invasive SCC in the specimen as well as to classify
histopathological features. HPV-DNA detection and genotyping
was performed using SPF10-DEIA-LiPA25 version 1 system
(Labo Biomedical Products, Rijswijk, Netherlands). All HPV-
DNA positive samples underwent RNA extraction and HPV-
E6∗I mRNA detection, as previously reported (19). All HPV16-
positive cases were further evaluated for HPV16-E5 mRNA
by reverse transcription quantitative PCR (RT-qPCR). The RT-
qPCR was designed to generate a 94 base pairs-long amplicon
within the HPV16-E5 gene, as previously described (13). BRYT-
Green R© based RT-qPCR was performed using Light Cycler R© 96
Real-Time PCR System (Roche Applied Science, USA) in a final
volume of 20µL reaction using GoTaq
R©
1-Step RT-qPCR System
(Promega, USA), 0.1µMof each forward and reverse primer and
3µL of RNA sample. The thermal cycler conditions programmed
were 15min at 37◦C and 10min at 95◦C, followed by 45 cycles
of 10 s at 95◦C, 10 s at 64◦C and 10 s at 72◦C. Following
amplification, melting curve analysis was performed to assess the
nature of the PCR product using a melting program with an
increase of 2.2◦C/s from 65 to 97◦C. RNA from cell lines 93-VU-
147T (originated from a floor of mouth squamous cell carcinoma,
kindly provided by J. Dorsman) and SCC-9 ATCC R© CRL-1629TM
(human tongue squamous cell carcinoma) were used as HPV16-
positive and HPV-negative controls, respectively. In all samples
that tested negative for the presence of HPV16-E5 mRNA, the
presence of the target HPV16-E5 DNA was confirmed by PCR
using the same amplification primers.
Histopathological Evaluation
We used Roche mtm Laboratories AG IHC (Heidelberg) for
p16INK4a determination. p16INK4a IHC was considered positive
when the pattern showed a strong and diffuse nuclear and
cytoplasmic staining in at least 70% of the cancer tissue (20).
A case was consider HPV-related if both HPV-DNA PCR
and p16INK4a IHC determination were positive, following the
recommendation from a previous study from our group (17) and
from a recent meta-analysis (21). Of note, all samples testing
double positive for HPV16-DNA and p16INK4a were also positive
for HPV E6∗I mRNA.
All HPV16/p16INK4a-positive samples as well as the stratified
random sample of HPV-negative cases were tested for IHC
staining for EGFR [anti-EGFR (3C6), Roche; pre-diluted]
and pEGFR [EP774Y, Abcam, (Tyr1068); dilution 1/300].
Membranous and sub-membranous cytoplasmic staining
was considered acceptable for either marker, according to
manufacturers’ data. EGFR protein and pEGFR expression
levels were evaluated semi-quantitatively and classified
as follows: Score 0: no staining or membrane staining in
<10% of tumor cells; Score 1+: faint membrane staining
in >10% of tumor cells; Score 2+: weak or moderate
complete membrane staining in >10% of tumor cells and
Score 3+: strong, complete membrane staining in >10% of
tumor cells. Scores of 0 and 1+ were considered negative
for either EGFR or pEGR expression while Scores 2+
and 3+ were considered positive. Representative images
for EGFR and pEGFR positive samples are displayed on
Figure 1.
Statistical Analyses
Conditional logistic models accounting for matching on tobacco
use were used to assess the association between HPV16-
positive OPCs and EGFR or pEGFR expression. Crude and
FIGURE 1 | Histopathological examples of OPC with EGFR (A) and pEGFR (B) expression.
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adjusted odds ratios for age, sex, alcohol consumption site, and
treatment, and their 95% confidence intervals were estimated.
Histological variables were not considered in multivariate
analyses, as previously described (22). Differences in baseline
characteristics between HPV16-positive and HPV-negative cases
were compared using the paired t-test for continuous variables
and the Fisher’s exact test for categorical variables. Agreement
between EGFR and pEGFR stratified by HPV status was
assessed through Kappa index and the distribution of discordant
responses from EGFR and pEGFR by using McNemar’s test.
Those were also used to assess the agreement/discordant
cells between HPV16-E5 and EGFR or pEGFR expression in
HPV16-positive OPC cases. For survival analysis only patients
with locally advanced disease (stage III, IVa,b 7th edition)
were included. Survival time was calculated from the date of
histological diagnosis to either time of death (overall survival,
OS) or to time of cancer recurrence (disease-free survival,
DFS). The cumulative probability of survival past five years
was estimated by Kaplan–Meier analysis. Survival curves were
compared by means of the log-rank test. All p-values obtained
were corrected for multiple testing by using the Benjamini-
Hochberg procedure with alpha = 0.05 significance level.
Multivariate Cox’s proportional hazards models were performed
under three scenarios to explore whether HPV16-positivity,
EGFR and pEGFR expression alone or any combination between
them could have a value as prognostic variables, after accounting
for other confounding factors (see Table 3 foot note). Hazard
ratios were calculated for death and recurrence for OPC patients.
FIGURE 2 | Samples disposition and testing for HPV status and all biomarkers.
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Statistical analyses were performed with STATA SE version 15.0
and R version 3.3.2.
RESULTS
Figure 2 describes the workflow of the OPC targeted cases,
samples collected, processed and tested. Among the 1,381
OPC patients targeted, a total of 788 samples yielded a valid
DNA result and were finally included in the analysis. HPV-
DNA positivity was found in 80 (10.2%) samples and HPV16
was the most frequent genotype, present in 67 cases (83.7%
among HPV-DNA positive cases). The number of bona-fide
HPV16-positive cases when considering double positivity for
HPV16-DNA and p16INK4a IHC was 53 (67.5% among HPV-
DNA positive cases). Hereinafter such double positive cases
will be referred to as HPV16-positive cases. A random sample
of 174 HPV-negative cases matched for tobacco use was also
included in the analysis as a control group. A demographical
and clinical descriptive of the OPC patients by HPV status
is summarized in Supplementary Table S1. HPV16-positive
patients were significantly more likely to be female, non-drinkers,
to have an undifferentiated tumor or to have a primary tonsil
tumor. The demographic and clinical characteristics associated
with HPV16-E5 expression, EGFR and pEGFR levels, stratified
by HPV status, as well as the crude Odds Ratio (OR) measures
of association are shown in Supplementary Table S2. The
percentage of HPV16-positive cases expressing also HPV16-
E5 was 77.4% (41/53). Since HPV16 integration often concurs
with E5 ablation, all samples that tested negative for the
presence of HPV16-E5 mRNA (12/53) were further tested for
HPV16-E5 DNA, and 58.3% (7/12) were positive. We confirmed
that these seven HPV16-E5 mRNA-negative/HPV16-E5 DNA-
positive samples were also positive for HPV-E6∗I mRNA, thus
excluding the possibility of a false negative for mRNA presence
by mRNA degradation.
We examined differential EGFR and pEGFR levels between
HPV16-positive OPCs and tobacco smoking-matched HPV-
negative OPCs and calculated the corresponding ORs (Table 1).
EGFR expression levels were significantly lower in HPV16-
positive OPCs than in HPV-negative: 37.7% (20/53) vs 70.8%
(119/168), respectively (OR = 0.15 [95% Confidence Interval
(CI): 0.04–0.56]). There were no differences in pEGFR expression
TABLE 1 | Association of differential EGFR and pEGFR levels between HPV16-positive OPCs and tobacco smoking-matched HPV-negative OPCs.




No/Total (%) No/Total (%)
EGFR EXPRESSION
Negative 49/168 (29.2) 33/53 (62.3) Ref.
Positive 119/168 (70.8) 20/53 (37.7) 0.15 [0.04–0.56]
pEGFR EXPRESSION
Negative 127/169 (75.1) 32/53 (60.4) Ref.
Positive 42/169 (24.9) 21/53 (39.6) 1.58 [0.48–5.17]
*Adjusted OR by EGFR expression, age, sex, alcohol consumption, and site. Cases matched by tobacco use (see details in Methods section). **Adjusted OR by pEGFR expression,
age, sex, alcohol consumption, and site. Cases matched by tobacco use (see details in Methods section).EGFR, Epidermal Growth Factor Receptor; pEGFR, phosphorylated EGFR;
HPV, Human Papillomavirus; OPC, Oropharyngeal carcinoma; OR, Odds Ratio; 95%CI, 95% Confidence Interval. HPV16 positive cases are also positive for p16INK4a.
TABLE 2a | Concordance between EGFR and pEGFR expression by HPV status.
EGFR expression pEGFR expression Kappa [95%CI] McNemar’s test
P-value
Negative Positive
N (%) N (%)
HPV16 POSITIVE
Negative 23 (43.4) 10 (18.9)
Positive 9 (17.0) 11 (20.8) 0.24 [−0.02 to 0.51] 1.000
HPV/DNA NEGATIVE
Negative 38 (22.6) 11 (6.5)
Positive 88 (52.4) 31 (18.5) 0.03 [−0.07 to 0.12] <0.001
HPV, Human Papillomavirus; EGFR, Epidermal Growth Factor Receptor; pEGFR, phosphorylated EGFR. DNA, Deoxyribonucleic acid; HPV16 positive cases are also positive for p16INK4a.
Kappa index: values <0 as indicating no agreement and 0–0.20 as slight, 0.21–0.40 as fair, 0.41–0.60 as moderate, 0.61–0.80 as substantial, and 0.81–1 as almost perfect agreement.
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levels between HPV16-positive and HPV-negative OPCs: 39.6%
(21/53) vs 24.9% (42/169), respectively (OR= 1.58 [95%CI: 0.48–
5.17]). Furthermore, as a sensitivity analysis, we reanalyzed the
data using unconditional logistic regression obtaining similar
results: for EGFR expression levels, OR = 0.22 [95%CI: 0.12–
0.52]; for pEGFR, OR = 2.02 [95%CI: 0.87–4.7]. Table 2a shows
the concordance between EGFR and pEGFR expression by HPV
status. Among HPV-negative OPC patients we observed an
unequal distribution of discordant samples, with an unbalance
toward higher proportion of EGFR-positive/pEGFR-negative
cases, not observed in HPV16-positive cases (McNemar’s test
p < 0.001 and 1.0, respectively). Within HPV16-positive cases,
no agreement was found between HPV16-E5 expression and
EGFR or pEGFR levels (Kappa = −0.03 and Kappa = −0.08,
respectively; Table 2b).
With a median follow-up of 39.36 months (min = 0.03
– max = 272.07), survival analyses were performed. We
examined the OS and DFS for OPC patients based on
Kaplan-Meier curves stratified by different biomarkers. We
first evaluated the role of each biomarker alone (Figure 3).
TABLE 2b | Concordance between HPV16-E5 expression and EGFR or pEGFR expression in HPV16 positive OPC cases.
E5 mRNA status EGFR expression Kappa [95%CI] McNemar’s test
P-value
Negative Positive
N (%) N (%)
Negative 7 (13.2) 5 (9.4)
Positive 26 (49.1) 15 (28.3) −0.03 [−0.23 to 0.16] <0.001
E5 mRNA status pEGFR expression Kappa [95%CI] McNemar’s test
P-value
Negative Positive
N (%) N (%)
Negative 6 (11.3) 6 (11.3)
Positive 26 (49.1) 15 (28.3) −0.08 [−0.29 to 0.12] <0.001
HPV, Human Papillomavirus; EGFR, Epidermal Growth Factor Receptor; pEGFR, phosphorylated EGFR. HPV16 positive cases are also positive for p16INK4a. Kappa index: values <0
as indicating no agreement and 0–0.20 as slight, 0.21–0.40 as fair, 0.41–0.60 as moderate, 0.61–0.80 as substantial, and 0.81–1 as almost perfect agreement.
FIGURE 3 | Overall survival and disease free survival of locally-advance OPC patients based on Kaplan-Meier curves stratified by biomarkers. Legend: Data on 5
years Overall Survival (A–C) and 5 years disease free survival (D–F) according to three different biomarkers: HPV16 (A,D), EGFR (B,E), and pEGFR (C,F). (A,D) Show
OS and DFS Kaplan-Meier curve for HPV16-related and HPV negative samples. (B,E) Show OS and DFS Kaplan-Meier curve for EGFR-positive and EGFR-negative
samples. (C,F) Show OS and DFS Kaplan-Meier curve for pEGFR-positive and pEGFR-negative samples.
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HPV16-positive cases demonstrated better OS (a) Log-rank
p < 0.001 and DFS (d) Log-rank p = 0.009. In the same
line, EGFR-negative cases demonstrated better OS (b) Log-
rank p = 0.033 and DFS (e) Log-rank p = 0.016. We did
not find differences related to pEGFR detection alone neither
in OS (c) Log-rank p = 0.778 nor in DFS (f) Log-rank
p= 0.430.
We further evaluated the differences in OS and DFS as
a function of the combination of HPV status and EGFR
expression (Figures 4A,C) and of HPV status and pEGFR levels
(Figures 4B,D). The analyses showed that stratification after
HPV positive/negative and EGFR or pEGFR positive/negative
resulted in differences in both OS and DFS (Log-rank p-values
indicated in the corresponding figure).
FIGURE 4 | Overall survival and disease free survival of of locally-advance OPC patients stratified by combination of HPV16 status and EGFR or pEGFR. Legend:
Data on 5 years Overall Survival (A,B) and 5 years disease free survival (C,D) according to the combination of HPV16 status and EGFR or pEGFR. (A,C) Show OS
and DFS Kaplan-Meier curve according to HPV16 status and EGFR expression. (B,D) Show OS and DFS Kaplan-Meier curve according to HPV16 status and pEGFR
expression. The H0 assumed that all groups have equal OS and DFS.
FIGURE 5 | Overall survival of locally-advanced HPV16-related patients stratified by HPV16-E5 alone and in combination with EGFR and pEGFR. Legend: Data on 5
years Overall Survival for HPV16-related patients, stratified by HPV16-E5 (A) the combination of HPV16-E5 and EGFR (B) and the combination of HPV16-E5 and
pEGFR (C). The H0 assumed that all groups have equal OS.
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Among HPV16-positive cases, when analyzing the impact on
survival of HPV16-E5 detection, patients with OPC expressing
E5 displayed better OS than E5-negative ones, but this difference
was not significant (Log-rank p = 0.148; Figure 5A). Finally,
evaluation of differences in OS and DFS as a function of the
combination of HPV16-E5 and EGFR (Figure 5B) or pEGFR
(Figure 5C) expression did not show differences between groups
(Log-rank p= 0.104 and Log-rank p= 0.263, respectively).
Hazard ratios (HR) for death and recurrence for OPC patients
are presented in Table 3, stratifying by HPV16-positivity, EGFR,
and pEGFR expression and their combinations. When all three
biomarkers were considered separately and after adjusting for
confounding covariates, differences in OS and DFS among
OPC patients remained statistically significant for HPV16-
positive compared to negative and for EGFR positive vs negative
regarding adjusted HR for DFS. When combining HPV16 status
and EGFR expression, HPV16-positive/EGFR-negative samples
demonstrated better OS than any other combination (HR= 0.13
[95%CI: 0.05–0.36]). For HPV16 status and pEGFR expression,
all combinations showed better OS compared to patients HPV-
negative/pEGFR-positive (p < 0.001).
DISCUSSION
Viral etiology (i.e., HPV-related status) is already well established
as an independent predictor of improved OS and treatment
responsiveness in OPCs (2, 5). Notwithstanding, not all patients
with HPV-related OPCs respond equally to treatment nor have
the same prognosis. With this study we have aimed at identifying
additional biomarkers beyond OPC-relatedness to better classify
HPV-related OPC patients, in an era where developing de-
escalation clinical trials is a translational research priority.
We have adhered to a strict definition of viral etiology
of OPC samples: an OPC was defined as HPV16-positive if
it tested positive for the presence of viral HPV16-DNA and
also displayed p16INK4a high expression—a cellular surrogate
marker for oncoviral activity (17). In our series, HPV16 was
the most frequently detected viral genotype, accounting for 83%
among HPV-DNA positive OPC samples, matching previous
descriptions for the oropharynx (18, 23). AmongHPV16-positive
samples, 77.4% expressed HPV16-E5, in agreement with Um
and coworkers, who described variable E5 expression in HPV16-
positive OPCs (13).
During chronic infection and malignization, viral DNA can
integrate into the cellular DNA (24, 25). Usually, this integration
event concurs with the loss of particular stretches of the viral
genome, often spanning the E2 and the E5 genes. For this
reason, in all twelve HPV16-E5 mRNA negative samples we
assessed the presence of the corresponding E5 target DNA, as
well as the expression of the HPV16-E6∗I mRNA. All twelve
samples were positive for E6 expression, further confirming viral
transcriptional activity and thus active viral gene expression.
Seven of them (58%) were HPV16-E5 DNA-positive, suggesting
that the E5 oncogene was present but its expression had been
shut down, either because of upstream disruption of the viral
genome or because of epigenetic silencing (26). In five of the
HPV16-E5 mRNA negative samples we could not detect the E5
DNA, suggesting that it had been probably deleted during an
integration event.
The E5 oncoprotein enhances the transforming activity of E6
and E7 (13). We therefore aimed at studying whether HPV16-
E5 expression could be an additional prognostic biomarker
for HPV16-positive OPC patients. In our series, detection of
HPV16-E5mRNA suggested an improved OS, but this trend was
not significant, possibly due to the limited size of our cohort
(N = 53). Our results thus are concordant with but cannot
confirm previous studies reporting an improved DFS, but not OS
for patients with cancers displaying high HPV16-E5 expression
levels (13).
EGFR is frequently reported to be overexpressed in HNSCC,
and such overexpression correlates with poor prognosis: almost
80% of HNSCC studies demonstrate decreased OS and DFS
for patients with cancers overexpressing EGFR (27). Mutations
in the EGFR gene, such as gene amplification or constitutive
activation are common among non HPV-related HNSCCs (8, 28,
29). Results from our series at the protein level are consistent
with this trend, as HPV-negative samples expressed more often
EGFR than HPV16-positive ones (71 vs 38%). Results from the
report by Kumar and coworkers. assessing EGFR expression
and HPV-relatedness status in OPCs (30) are consistent with
those communicated here, but in their case EGFR expression
was higher for both groups (93 vs 78%, respectively). This large
variation, most notable among HPV-positive cases, can stem
from (i) the different evaluation criteria used for assessing EGFR
expression (their three-tier vs our two-tier classification scheme),
(ii) the HPV-relatedness definition use (more strict in our case),
or (iii) may simply be related to sample size, our cohort being
almost four times larger size (50 vs 221).
While there is a good agreement in the literature about the
higher EGFR expression among HPV-negative OPC cases, this
is not the case for pEGFR levels. A previous study has reported
higher pEGFR levels among HPV-negative OPCs (31), but our
results contradict this view. In our series, the strong increase
in EGFR levels among HPV-negative OPCs was accompanied
by a sensible albeit non-significant decrease in pEGFR levels, to
the extent that HPV16-positive samples displayed higher pEGFR
positivity than HPV-negative samples (40 vs 25%, respectively).
Our rationale to seek a connection between HPV16-E5
expression and increased EGFR levels stems from the known
functional impact of HPV16-E5 on EGFR-mediated signaling.
Extracellular binding of the EGF ligand leads to activation of
EGFR through intracellular phosphorylation. The activated form
pEGFR is internalized, driven to the endosomes and eventually
degraded. Presence of HPV16-E5 results in inability for late
endosomal acidification (16), preventing pEGFR degradation,
which is instead vehiculated again to the cellular surface in
activated state, overall resulting in an increased ligand-triggered
EGFR response that is maintained even after the EGF stimulus
has disappeared (15). Under this view, we initially hypothesized
that higher HPV16-E5 expression would result in increased
pEGFR surface recycling, and thus, higher pEGFR positivity. Our
results however failed to validate our mechanistic hypothesis, as
HPV16-E5 expression was not related to pEGFR expression in
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our series. Nevertheless, our results show that HPV16-positive
cancers display lower EGFR levels but higher pEGFR/EGFR
ratios than HPV-negative cancers. We are not aware of any viral
mechanism to explain this puzzling observation.
High EGFR levels are associated with worse prognosis in
HNSCC (32), as well as in a subset of HPV-related OPCs (7).
In line with these results and with other studies (30, 33), we
confirm in our cohort an association between EGFR expression
andworse prognosis. The combination of both biomarkers, HPV-
relatedness and EGFR or pEGFR expression, could be useful
to better characterize OPC patients. When different variables
(i.e., age, tobacco use) were entered into a multivariate Cox
proportional hazards model, HPV status and the combination
of HPV-relatedness and EGFR or pEGFR expression were
predictors of better OS and DFS. This result contradicts however
the study by Romanitan and coworkers, where pEGFR was not
found to be an optimal prognostic marker for clinical outcome in
OPC patients (31). Furthermore, Bossi and coworkers reviewed
in a recent article the prognostic and predictive value of EGFR
in HNSCC (34), regarding HPV-positive patients they described
different trials evaluating the combined effect of HPV status
and EGFR expression on prognosis, showing that patients with
EGFR-positive/HPV-negative cancer have the poorest outcomes,
while the EGFR negative/HPV-positive group showed the best
outcome in line with our results. Nevertheless, they suggest that
in recent studies including OPC patients, the prognostic role
of EGFR expression was related to the association with HPV-
negative tumors, and the added value of EGFR analysis seems to
be marginal in respect to HPV (34).
Limited preclinical data investigating the combination of
radiotherapy and anti-EGFR antibodies are available and clinical
data are still controversial for HPV-related patients (35–37). In
our series, only four patients with locally advanced HPV16-
positive OPC were treated with anti-EGFR therapy concomitant
with radiotherapy. So far, no conclusion can thus be drawn
about the use of anti-EGFR therapy, HPV-relatedness and
HPV16-E5 expression and EGFR and pEGFR levels in the
context in our series. Interestingly, two of the phase III clinical
trials investigating the combination of anti-EGFR therapy with
radiotherapy compared to the standard treatment with chemo-
radiotherapy for HPV-positive oropharyngeal cancer patients,
the RTOG 1026 and the DE-ESCALaTE study, have been
recently presented. Both studies demonstrated superiority for
the standard treatment (cisplatin-radiotherapy) for HPV-related
OPC patients (38–40).
Our study has a number of limitations. First, the HPV-
related attributable fraction among OPCs in Mediterranean
countries is lower than in other World regions, such as the
US or Northern Europe. Thus, despite having analyzed a large
global number of OPC cases, our cohort included a low number
of HPV-related OPC patients. This reduced effective sample
size limits our power to establish the validity of E5 mRNA
expression as a potential biomarker. Second, the analyses for this
pilot study were performed on FFPE samples. Although such
fixation technique is the most common approach to stabilize
tissue prior to anatomopathological analyses, this aggressive
chemical treatment may impact the quantity and quality of
the retrieved nucleic acids, potentially rendering lower apparent
prevalence values of viral DNA and/or mRNA. Third, pEGFR
detection is still not widely implemented in the clinical setting,
and the determination here applied was semi-quantitative. All
in all, these limitations may have hindered the identification of
a putative connection between viral HPV16-E5 expression and
the detection of cellular EGFR/pEGFR. On the other hand, the
strength of our study is the epidemiology design: we have applied
a robust HPV testing method, performed in a single laboratory,
to decrease variability; we have only included oropharyngeal
samples and excluded other head and neck sub-sites; and we have
focused on samples positive only for one single HPV genotype
(HPV16).
In summary, our study demonstrates HPV16-E5 to be highly
expressed on HPV16-positive OPC samples. HPV-negative
samples expressed significantly more EGFR, while HPV16-
positive samples expressed more pEGFR. The combinations of
HPV-relatedness and EGFR or pEGFR protein levels are useful
biomarkers for prognosis outcome in OPC patients. Specifically,
OPC patients with HPV16-positive and EGFR negative cancers
present better OS prognosis than patients with HPV-negative
and EGFR positive cancers. Further studies are warranted to
better understand the role of HPV16-E5 in cancer etiology and
its relationship with EFGR and pEGFR expression.
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